Subcutaneous infliximab may be cost saving for treating rheumatoid arthritis in the UK.

The base case assumed an administration cost of £382 and productivity gains of 3.5h for IV induction and 2h per maintenance therapy; the dose-escalating scenario assumed that 53.26% of the population receive dose escalation from 3 to 5-7 mg/kg at an administration cost of £154. Introducing the subcutaneous biosimilar of infliximab, CT-P13 SC [Celltrion Healthcare], may lead to substantial cost savings in the first 5 years - primarily due to lower administrative costs - for treating patients with rheumatoid arthritis (RA) in the UK, according to research published in I Applied Health Economics and Health Policy i .[1] The researchers conducted a prevalence-based model that used epidemiological data, administration cost data, and market share data to compare a "world with" SC infliximab scenario to a "world without" SC infliximab (IV infliximab only) from a societal perspective. [Extracted from the article]